Loading...
•
Jun 30
AstraZeneca Q2 2025 Earnings Report
AstraZeneca reported strong Q2 2025 performance with robust revenue growth and solid profitability across its core business areas.
Key Takeaways
AstraZeneca delivered a strong Q2 2025 with $14.46 billion in revenue and $3.5 billion in net income. The company saw continued growth in its oncology, biopharmaceuticals, and rare disease portfolios, supported by new molecular entities entering Phase III trials.
Q2 2025 revenue reached $14.46 billion, up 11% at constant exchange rates
Reported EPS was $1.09 per ADS; Core EPS was $2.17 per share
Net income for the quarter was $3.5 billion with operating income at $4.584 billion
Five new molecular entities advanced to Phase III trials, supporting future pipeline momentum
AstraZeneca
AstraZeneca
AstraZeneca Revenue by Segment
AstraZeneca Revenue by Geographic Location
Revenue by Segment
Oncology Revenue
CapyFin.comCVRM Revenue
CapyFin.comR&I Revenue
CapyFin.comRare Disease Revenue
CapyFin.comV&I Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comChina Revenue
CapyFin.comEx-China Revenue
CapyFin.comEstablished Rest of World Revenue
CapyFin.com Forward Guidance
AstraZeneca reiterated its FY 2025 guidance, expecting high single-digit revenue growth and low double-digit Core EPS growth.
Positive Outlook
- Strong performance across oncology and rare disease portfolios
- Solid pipeline momentum with multiple Phase III readouts
- Operational leverage through SG&A efficiency
- 27% increase in net cash inflow from operations in H1 2025
- Expected neutral impact from FX on Total Revenue and Core EPS
Challenges Ahead
- Continued pressure from biosimilars on legacy rare disease products
- Brilinta sales impacted by generics
- Some regional revenue fluctuations due to tender market dynamics
- Elevated R&D and SG&A expenses relative to H1 2024
- Tax rate increased slightly compared to previous periods